Aucune remarque pour cette diapositive
> Over the last decade, a tremendous amount of data has been published on how cancers generate immune tolerance.
> We know now that within the tumor micro-environment, there are subsets of myeloid cells, which, together with the Tumor cells, sustain the development of a type of lymphocytes, called regulatory T-cells or Tregs.
These Tregs are a subset of CD4+ T-cells identified by the expression of a transcription factor called FOXP3 and have the ability to inhibit specifically the immune response directed against the tumor.
In order to treat cancers, people have been focusing so far on the tumor cells.
A paradigm shift is happening today in cancer therapy where instead of targeting the tumor cells, new molecules are designed to target the immune system in order to break the cancer tolerance and stimulate the anti-tumor immune response.
Interestingly, it has also been shown recently that inflammatory cells of the myeloid lineage are of bad prognosis in NB.